<template xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="openEHR/v1/Template"><id>9851da07-786c-4655-98cb-0cc5818b8f8c</id><name>Graft vs Host Disease Pediatrics Order Set</name><description><lifecycle_state>Initial</lifecycle_state><details><purpose/><use/><misuse/></details><other_details><item><key>MetaDataSet:Sample Set </key><value>Template metadata sample set </value></item><item><key>Acknowledgements</key><value/></item><item><key>Business Process Level</key><value/></item><item><key>Care setting</key><value/></item><item><key>Client group</key><value/></item><item><key>Clinical Record Element</key><value/></item><item><key>Copyright</key><value/></item><item><key>Issues</key><value/></item><item><key>Owner</key><value/></item><item><key>Sign off</key><value/></item><item><key>Speciality</key><value/></item><item><key>User roles</key><value/></item></other_details></description><annotations path="[openEHR-EHR-SECTION.adhoc.v1]"><items><item><key>Technical.ﻩ Technical Traceability</key><value>{~AHSID~9851da07-786c-4655-98cb-0cc5818b8f8c~NAME~Graft vs Host Disease Pediatrics Order Set}</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.clinical_guidance.v1]"><items><item><key>Transform.Technical Notes</key><value>&lt;p&gt;Order Set Keywords: Cancer, GVHD, BMT, Skin, Liver, Gut, GI, HCT, cellular therapy&lt;/p&gt;</value></item><item><key>CKT.Clinical Guidance</key><value>&lt;p&gt;&lt;em&gt;Consider Opening and merging the following order sets:&lt;/em&gt;&lt;/p&gt;&lt;p&gt;&lt;em&gt;- BMT Admission Pediatrics&lt;/em&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;General&apos;]/items[openEHR-EHR-SECTION.clinical_guidance.v1 and name/value=&apos;Clinical Decision Support - Acute&apos;]"><items><item><key>CKT.Clinical Guidance</key><value>&lt;p&gt;&lt;u&gt;&lt;strong&gt;Grading of Acute GVHD&lt;/strong&gt;&lt;/u&gt;&lt;/p&gt;&lt;table cellpadding=&quot;1&quot; cellspacing=&quot;1&quot; border=&quot;1&quot; style=&quot;width:455px&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;7&quot; style=&quot;width:402px&quot;&gt;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;Stage&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Grade&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;2&quot;&gt;Skin&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;2&quot;&gt;Liver&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;2&quot; style=&quot;width:125px&quot;&gt;Upper Gut&lt;/td&gt;&lt;td style=&quot;width:72px&quot;&gt;Lower Gut&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&amp;nbsp; 0&lt;/td&gt;&lt;td&gt;&amp;nbsp; 0&lt;/td&gt;&lt;td&gt;And&lt;/td&gt;&lt;td&gt;&amp;nbsp; 0&lt;/td&gt;&lt;td&gt;And&lt;/td&gt;&lt;td style=&quot;width:73px&quot;&gt;&amp;nbsp; 0&lt;/td&gt;&lt;td style=&quot;width:59px&quot;&gt;And&lt;/td&gt;&lt;td style=&quot;width:72px&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&amp;nbsp; I&lt;/td&gt;&lt;td&gt;&amp;nbsp; 1-2&lt;/td&gt;&lt;td&gt;And&lt;/td&gt;&lt;td&gt;&amp;nbsp; 0&lt;/td&gt;&lt;td&gt;And&lt;/td&gt;&lt;td style=&quot;width:73px&quot;&gt;&amp;nbsp; 0&lt;/td&gt;&lt;td style=&quot;width:59px&quot;&gt;And&lt;/td&gt;&lt;td style=&quot;width:72px&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&amp;nbsp; II&amp;nbsp;&lt;/td&gt;&lt;td&gt;&amp;nbsp; 3&lt;/td&gt;&lt;td&gt;Or&lt;/td&gt;&lt;td&gt;&amp;nbsp; 1&lt;/td&gt;&lt;td&gt;Or&lt;/td&gt;&lt;td style=&quot;width:73px&quot;&gt;&amp;nbsp; 1&lt;/td&gt;&lt;td style=&quot;width:59px&quot;&gt;Or&lt;/td&gt;&lt;td style=&quot;width:72px&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&amp;nbsp; III&lt;/td&gt;&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;td&gt;&amp;nbsp;&lt;/td&gt;&lt;td&gt;&amp;nbsp; 2-3&lt;/td&gt;&lt;td&gt;Or&lt;/td&gt;&lt;td style=&quot;width:73px&quot;&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;&lt;td style=&quot;width:59px&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td style=&quot;width:72px&quot;&gt;2-3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&amp;nbsp; IV&lt;/td&gt;&lt;td&gt;&amp;nbsp; 4&lt;/td&gt;&lt;td&gt;Or&lt;/td&gt;&lt;td&gt;&amp;nbsp; 4&lt;/td&gt;&lt;td&gt;Or&lt;/td&gt;&lt;td style=&quot;width:73px&quot;&gt;&amp;nbsp;&amp;nbsp;&lt;/td&gt;&lt;td style=&quot;width:59px&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td style=&quot;width:72px&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;u&gt;&lt;strong&gt;Consensus organ staging and overall clinical grading for Acute GVHD&lt;/strong&gt;&lt;/u&gt;&lt;/p&gt;&lt;table cellpadding=&quot;1&quot; cellspacing=&quot;1&quot; border=&quot;1&quot; style=&quot;width:869px&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style=&quot;width:48px&quot;&gt;Stage&lt;/td&gt;&lt;td style=&quot;width:167px&quot;&gt;Skin&lt;/td&gt;&lt;td style=&quot;width:144px&quot;&gt;Liver&lt;/td&gt;&lt;td style=&quot;width:159px&quot;&gt;Upper GI&lt;/td&gt;&lt;td style=&quot;width:368px&quot;&gt;Gut&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;width:48px&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width:167px&quot;&gt;No rash&lt;/td&gt;&lt;td style=&quot;width:144px&quot;&gt;Total bilirubin less than 34 umol/L&lt;/td&gt;&lt;td style=&quot;width:159px&quot;&gt;No or intermittend nausea, vomiting or anorexia&lt;/td&gt;&lt;td style=&quot;width:368px&quot;&gt;Diarrhea less than 500 mL/day or 10 mL/kg/day or 300 mL/m2/day&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;width:48px&quot;&gt;1&lt;/td&gt;&lt;td style=&quot;width:167px&quot;&gt;Maculopapular rash less than 25% body surface area&lt;/td&gt;&lt;td style=&quot;width:144px&quot;&gt;Total bilirubin 34 to 50 umol/L&lt;/td&gt;&lt;td style=&quot;width:159px&quot;&gt;Persistent nausea, vomiting or anorexia&lt;/td&gt;&lt;td style=&quot;width:368px&quot;&gt;Diarrhea between 500-999 mL/day or 10 - 19.9 mL/kg/day or 300 – 600 mL/m2/day&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;width:48px&quot;&gt;2&lt;/td&gt;&lt;td style=&quot;width:167px&quot;&gt;Maculopapular rash 25 – 50% body surface area&lt;/td&gt;&lt;td style=&quot;width:144px&quot;&gt;Total bilirubin 51 to 100 umol/L&lt;/td&gt;&lt;td style=&quot;width:159px&quot;&gt;--&lt;/td&gt;&lt;td style=&quot;width:368px&quot;&gt;Diarrhea between 1000 – 1499 mL/day or 20 -29.9 mL/kg/day or 600 - 900 mL/m2/day&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;width:48px&quot;&gt;3&lt;/td&gt;&lt;td style=&quot;width:167px&quot;&gt;Maculopapular rash greater than 50% body surface area&lt;/td&gt;&lt;td style=&quot;width:144px&quot;&gt;Total bilirubin 101 to 255 umol/L&lt;/td&gt;&lt;td style=&quot;width:159px&quot;&gt;--&lt;/td&gt;&lt;td style=&quot;width:368px&quot;&gt;Diarrhea greater than 1500 mL/day or 30 mL/kg/day or 900 mL/m2/day&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;width:48px&quot;&gt;4&lt;/td&gt;&lt;td style=&quot;width:167px&quot;&gt;Generalized exfoliative, ulcerative or bullous dermatitis&lt;/td&gt;&lt;td style=&quot;width:144px&quot;&gt;Total bilirubin greater than 255 umol/L&lt;/td&gt;&lt;td style=&quot;width:159px&quot;&gt;--&lt;/td&gt;&lt;td style=&quot;width:368px&quot;&gt;Severe abdominal pain, with or without ileus, and/or grossly bloody stool (regardless of stool volume)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;General&apos;]/items[openEHR-EHR-SECTION.clinical_guidance.v1 and name/value=&apos;Clinical Decision Support - Chronic&apos;]"><items><item><key>CKT.Clinical Guidance</key><value>&lt;table border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Organ&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Score 0&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Score 1&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Score 2&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Score 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;strong&gt;SKIN&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&amp;lt;19% BSA with disease signs but NO sclerotic features&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;19-50% BSA OR involvement with superficial sclerotic features “not hidebound” (able to pinch)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&amp;gt;50% BSA OR deep sclerotic features “hidebound” (not able to pinch) OR impaired mobility, ulceration, or severe pruritis&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;strong&gt;MOUTH&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Mild symptoms with disease signs but not limiting oral intake significantly&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Moderate symptoms with disease signs with partial limitation of oral intake&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Severe symptoms with disease signs on examination with major limitation of oral intake&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;strong&gt;EYES&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Mild dry eye symptoms not affecting ADL (requiring eyedrops &amp;lt; 3 times daily) OR asymptomatic signs of keratoconjunctivitis sicca&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Moderate dry eye symptoms partially affecting ADL (requiring drops &amp;gt;3 times daily or puntal plugs) WITHOUT vision impairment&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Severe dry eye symptoms significantly affecting ADL (special eyewear to relieve pain) OR unable to work because of ocular symptoms) OR loss of vision caused by keratoconjunctivitis sicca&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;strong&gt;GI TRACT&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Symptoms such as dysphagia, anorexia, nausea, vomiting, abdominal pain or diarrhea without significant weight loss (&amp;lt;5%)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Symptoms associated with mild to moderate weight loss (5-15%)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Symptoms associated with significant weight loss &amp;gt;15%, requires nutritional supplement for most calorie needs OR esophageal dilation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;strong&gt;LIVER&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Normal LFT&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Bilirubin (total) normal&lt;/p&gt;&lt;p&gt;ALT 180-300 U/L&lt;/p&gt;&lt;p&gt;ALP ≥429 U/L&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Bilirubin 24-72 umol/L&lt;/p&gt;&lt;p&gt;ALT &amp;gt;300 U/L&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Bilirubin &amp;gt;72 umol/L&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;strong&gt;LUNGS&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;p&gt;FEV1 &amp;gt;80%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Mild symptoms (shortness of breath after climbing 1 flight of steps), or&lt;/p&gt;&lt;p&gt;FEV1 60-79%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Moderate symptoms (shortness of breath after walking on flat ground), or&lt;/p&gt;&lt;p&gt;FEV1 40-59%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Severe symptoms (shortness of breath at rest requiring O2), or&lt;/p&gt;&lt;p&gt;FEV1 &amp;lt;39%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;strong&gt;JOINTS &amp;amp; FASCIA&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Mild tightness of arms or legs, normal or mild decreased range of motion AND not affecting ADL&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Tightness of arms or legs OR joint contractures, erythema thought due to fascitis, moderate decreased range of motion AND mild to moderate limitation of ADL&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Contractures WITH significant decrease of range of motion AND significant limitation of ADL (unable to tie shoes, button shirt, dress self)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;strong&gt;GENITAL TRACT*&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;No symptoms/signs&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Mild signs*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Moderate signs*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Severe signs*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;em&gt;*Genital signs:&lt;/em&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Female genitalia:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;1) Mild (any of the following); erythema on vulvar mucosal surfaces, vulvar lichen-planus or vulvar lichen-sclerosis.&lt;/p&gt;&lt;p&gt;2) Moderate (any of the following); erosive inflammatory changes of the vulvar mucosa, fissures in vulvar folds&lt;/p&gt;&lt;p&gt;3) Severe (any of the following); labial fusion, clitoral hood agglutination, fibrinous vaginal adhesions, circumferential fibrous vaginal banding, vaginal shortening, synechia, dense sclerotic changes, and complete vaginal stenosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Male genitalia:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;1) Mild: lichen planus-like feature;&lt;/p&gt;&lt;p&gt;2) Moderate: lichen sclerosus-like feature or moderate erythema;&lt;/p&gt;&lt;p&gt;3) Severe: phimosis or urethral/meatal scarring.&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;NIH Global Severity Score:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Mild cGVHD:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;•&amp;nbsp;&lt;strong&gt;≤2 organs involved with max organ score 1, plus lung score 0&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Moderate cGVHD:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;•&amp;nbsp;&lt;strong&gt;≥3 organs involved with max score 1, or&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;•&amp;nbsp;&lt;strong&gt;≥1 organ (not lung) with a score of 2, or&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;•&amp;nbsp;&lt;strong&gt;Lung score 1&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Severe cGVHD:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;•&amp;nbsp;&lt;strong&gt;≥1 organ with a score of 3, or&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;•&amp;nbsp;&lt;strong&gt;Lung score 2 or 3&lt;/strong&gt;&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Medications&apos;]/items[openEHR-EHR-SECTION.clinical_guidance.v1]"><items><item><key>CKT.Clinical Guidance</key><value>&lt;p&gt;First Line Treatment of Acute GVHD is corticosteriods.&lt;/p&gt;&lt;p&gt;Second Line Treatment of Acute GVHD (Steroid-Refractory) is Ruxolitnib (Ruxolitinib is currently a non-formulary medication, it is available off the facility list as needed)&lt;/p&gt;&lt;p&gt;Ruxolitinib suggested dosing:&lt;/p&gt;&lt;p&gt;- less than 25 kg: 2.5 mg BID,&lt;/p&gt;&lt;p&gt;- greater than 25 kg or greater than 12 years old: 5 mg BID&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Medications&apos;]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Topical Agents&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;betamethasone valerate cream 0.1%; topical, 2 times per day, as scheduled&apos;]/activities[at0001]"><items><item><key>CKT.Content Details</key><value>&lt;p&gt;&amp;nbsp;Apply sparingly to affected body area&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Medications&apos;]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value=&apos;Topical Agents&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;hydrocortisone acetate cream 1%; topical, 2 times per day, as scheduled&apos;]/activities[at0001]"><items><item><key>CKT.Content Details</key><value>&lt;p&gt;&amp;nbsp;Apply to affected body area&lt;/p&gt;</value></item></items></annotations><definition xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" name="Graft vs Host Disease Pediatrics Order Set"><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" path="/items"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="General"><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="Clinical Decision Support - Acute"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="Clinical Decision Support - Chronic"/></Item><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Laboratory Investigations Routine"><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Chemistry"><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" template_id="f13a6eb8-7f1e-48a0-ba99-9f913ccef228" concept_name="Chronic GVHD Labs Pediatric Order Group" max="1" path="/items" name="Chronic GVHD Labs"/></Item><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Therapeutic Drug Monitoring and Toxicology"><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="866222b6-a0ad-4130-bc21-393c197e7c20" concept_name="LAB Cyclosporine Level Pre-dose Order" max="1" path="/items" name="Cyclosporine Level, Pre-dose; Mon/Wed/Fri Per Medication Dosing; Blood, Central Line"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="168a348b-b31f-425e-bf9b-5a7f8c29ff51" concept_name="LAB Tacrolimus Level Order" max="1" path="/items" name="Tacrolimus Level; Mon/Wed/Fri Per Medication Dosing; Blood, Central Line"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="fbad9375-d4fa-4c09-9c60-01dd6430a3e5" concept_name="LAB Sirolimus Level Order" max="1" path="/items" name="Sirolimus Level; Weekly Per Medication Dosing; Blood, Central Line"/></Item></Item><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Medications"><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="Clinical Decision Support"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" template_id="99ae2d5e-87e1-4934-8866-cca654ea762f" concept_name="Corticosteroid aGVHD first line treatment oncology pediatrics order group" max="1" path="/items" name="Corticosteroids"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" template_id="656e1e5f-635d-4a82-b903-b9cd0b88603e" concept_name="Immunosuppressive Agents Oncology Pediatrics Order Group" max="1" path="/items" name="Immunosuppressive Agents"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Topical Agents"><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="68478d78-bb7b-431c-8470-45234d1e6f77" concept_name="PHARM betamethasone valerate Cream 0.1% Order" max="1" path="/items" name="betamethasone valerate cream 0.1%; topical, 2 times per day, as scheduled"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="32f6be99-5710-4516-bbe7-fdd2016c92e2" concept_name="PHARM hydrocortisone acetate Cream 1% Order" max="1" path="/items" name="hydrocortisone acetate cream 1%; topical, 2 times per day, as scheduled"/></Item><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Ophthalmic Drops"><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="91a840ff-6950-4a9d-84b8-aa9615865862" concept_name="PHARM prednisoLONE acetate Eye drop 0.12% Order" max="1" path="/items" name="prednisoLONE acetate drop eye 0.12%; 1 drop, BOTH eyes, 2 times per day, as scheduled"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="ecba7cad-75a6-46d7-b0f9-abb2c0ef4998" concept_name="PHARM prednisoLONE acetate Eye drop 1% Order" max="1" path="/items" name="prednisoLONE acetate drop eye 1%; 1 drop, BOTH eyes, 2 times per day, as scheduled"/></Item><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Other Medications"><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="f1133e85-8cd4-4835-8a35-21a337082f0a" concept_name="PHARM cycloSPORINE Oral liquid 100 mg/mL Order" max="1" path="/items" name="cycloSPORINE liquid oral 100 mg/mL; 5 mL, swish and spit, 4 times per day, as scheduled"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="9cc7f7fc-f36b-44b3-a569-ba28fe6de1d7" concept_name="PHARM betamethasone sodium phosphate Enema 5 mg/100 mL Order" max="1" path="/items" name="betamethasone sodium phosphate enema 5 mg/100 mL; 5 mL, swish and spit, 4 times per day, as scheduled"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="809886da-c326-49f5-8fa9-9aaaa6cbc5d5" concept_name="PHARM beclomethasone 1 mg_mL Liquid Oral Order" max="1" path="/items" name="beclomethasone liquid oral 1 mg/mL; ***, oral, daily, as scheduled"/></Item></Item></definition><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.datetimeorderquestion.v1"><digest id="MD5-CAM-1.0.1">37AE50193A7EA542A4F219FF051EE95B</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.booleanorderquestion.v1"><digest id="MD5-CAM-1.0.1">56B5A2F2979B94F83C97E66B46679692</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1"><digest id="MD5-CAM-1.0.1">AD8DFB192E67715F0D9E11E95E674AD0</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.orderable_section.v1"><digest id="MD5-CAM-1.0.1">A89AC74BC8CAD3F0719579389C69006F</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.adhoc.v1"><digest id="MD5-CAM-1.0.1">8AE70853975A75254E6D39A8DE3652AF</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1"><digest id="MD5-CAM-1.0.1">4B2F0F6CD593E442DA9C30277A3EA9CF</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.freetextorderquestion.v1"><digest id="MD5-CAM-1.0.1">5DC6E2FC9E91ADD05E7C5B3E06F83D23</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.service_request_information.v1"><digest id="MD5-CAM-1.0.1">230A8D964017E1FD7AC82EBDEE0202A6</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1"><digest id="MD5-CAM-1.0.1">A7EC4E4C870D8C3431B29F6514353416</digest></integrity_checks></template>
